Personalis, Inc. (PSNL) EBITDA
- 2026-06-30: Basis Reported; EBITDA -$31.18M; Operating income (m); Depreciation and amortization (m).
- 2026-03-31: Basis Reported; EBITDA -$29.79M; Operating income (m); Depreciation and amortization (m).
- 2025-12-31: Basis Reported; EBITDA -$22.8M; Operating income (m); Depreciation and amortization (m).
- 2025-09-30: Basis Reported; EBITDA -$20.83M; Operating income (m); Depreciation and amortization (m).
Historical EBITDA
EBITDA 3 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | Reported | -$31.18M | (m) | (m) | $22.36M | -139.45% | $3.78M* | -$25.77M* | (m) | $16.34M | $22.00M | $5.00K |
| 2026-03-31 | Reported | -$29.79M | (m) | (m) | $15.47M | -192.54% | $3.19M | -$22.48M | (m) | $14.54M | $17.90M | $16.00K |
| 2025-12-31 | Reported | -$22.8M | (m) | (m) | $17.35M | -131.47% | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | Reported | -$20.83M | (m) | (m) | $14.5M | -143.67% | $1.63M* | -$21.80M* | (m) | $12.17M | $13.03M | $3.00K |
| 2025-06-30 | Reported | -$19.3M | (m) | (m) | $17.2M | -112.21% | $290.00K* | -$12.94M* | (m) | $12.38M | $14.18M | $2.00K |
| 2025-03-31 | Reported | -$15.11M | (m) | (m) | $20.61M | -73.33% | $2.51M | -$17.96M | (m) | $12.64M | $12.26M | $7.00K |
| 2024-12-31 | Reported | -$15.57M | (m) | (m) | $16.8M | -92.67% | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | Reported | -$11.58M | (m) | (m) | $25.71M | -45.05% | $247.00K* | -$6.20M* | (m) | $11.68M | $11.44M | $3.00K |
| 2024-06-30 | Reported | -$14.09M | (m) | (m) | $22.58M | -62.41% | $6.00K* | -$10.74M* | (m) | $12.96M | $11.97M | $4.00K |
| 2024-03-31 | Reported | -$16.04M | (m) | (m) | $19.53M | -82.17% | $104.00K | -$20.41M | (m) | $12.77M | $11.60M | $7.00K |
| 2023-12-31 | Reported | -$21.07M | (m) | (m) | $19.68M | -107.06% | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | Reported | -$27.99M | (m) | (m) | $18.25M | -153.41% | $868.00K* | -$16.68M* | (m) | $16.74M | $11.97M | $28.00K |
| 2023-06-30 | Reported | -$22.55M | (m) | (m) | $16.7M | -135.01% | $2.74M* | -$10.41M* | (m) | $17.85M | $12.13M | $36.00K |
| 2023-03-31 | Reported | -$27.04M | (m) | (m) | $18.86M | -143.39% | $3.78M | -$15.74M | (m) | $16.57M | $14.10M | $14.00K |
| 2022-12-31 | Reported | -$29.13M | (m) | (m) | $16.72M | -174.20% | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | Reported | -$25.36M | (m) | (m) | $14.86M | -170.68% | $21.41M* | -$14.77M* | (m) | $14.96M | $14.78M | $11.00K |
| 2022-06-30 | Reported | -$26.08M | (m) | (m) | $18.24M | -142.99% | $10.31M* | -$27.35M* | (m) | $16.29M | $15.87M | $14.00K |
| 2022-03-31 | Reported | -$26.53M | (m) | (m) | $15.23M | -174.24% | $8.63M | -$11.36M | (m) | $17.10M | $15.49M | $7.00K |
| 2021-12-31 | Reported | -$18.62M | (m) | (m) | $20.68M | -90.05% | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-09-30 | Reported | -$16.19M | (m) | (m) | $22.26M | -72.73% | $2.96M* | -$17.88M* | (m) | $13.62M | $12.14M | $12.00K |
| 2021-06-30 | Reported | -$13.55M | (m) | (m) | $21.67M | -62.51% | $4.11M* | -$25.93M* | (m) | $11.69M | $11.43M | $8.00K |
| 2021-03-31 | Reported | -$10.97M | (m) | (m) | $20.88M | -52.52% | $439.00K | -$11.74M | (m) | $9.50M | $10.42M | -$3.00K |
| 2020-12-31 | Reported | -$11.89M | (m) | (m) | $20.18M | -58.94% | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-09-30 | Reported | -$8.15M | (m) | (m) | $19.82M | -41.14% | $1.55M* | -$16.12M* | (m) | $7.19M | $7.79M | $5.00K |
| 2020-06-30 | Reported | -$8.1M | (m) | (m) | $19.5M | -41.54% | $779.00K* | -$15.35M* | (m) | $6.46M | $7.71M | $4.00K |
| 2020-03-31 | Reported | -$8.23M | (m) | (m) | $19.16M | -42.95% | $76.00K | -$8.64M | (m) | $6.39M | $7.27M | $30.00K |
| 2019-12-31 | Reported | -$5.83M | (m) | (m) | $18.15M | -32.11% | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-09-30 | Reported | -$4.53M | (m) | (m) | $17.15M | -26.41% | $3.67M* | -$9.64M* | (m) | $5.30M | $6.06M | $1.00K |
| 2019-06-30 | Reported | -$2.96M | (m) | (m) | $15.83M | -18.71% | $1.84M* | -$10.90M* | (m) | $4.50M | $5.47M | $2.00K |
| 2019-03-31 | Reported | -$4.38M | (m) | (m) | $14.08M | -31.15% | $960.00K | $66.00K | (m) | $5.25M | $4.17M | $2.00K |
| 2018-12-31 | Reported | -$2.13M | (m) | (m) | $13.16M | -16.20% | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-09-30 | Reported | -$851,000.00 | (m) | (m) | $11.65M | -7.30% | $1.94M* | -$431.00K* | (m) | $3.57M | $2.66M | $2.00K |
| 2018-06-30 | Reported | -$3.01M | (m) | (m) | $8.8M | -34.19% | (m) | (m) | (m) | $3.50M | $2.60M | $1.00K |
EBITDA 12 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | Reported | -$78.01M | (m) | (m) | $69.65M | -112.01% | $4.50M | -$74.95M | (m) | $50.26M | $53.57M | $21.00K |
| 2024-12-31 | Reported | -$57.33M | (m) | (m) | $84.61M | -67.75% | $1.60M | -$45.15M | (m) | $48.91M | $46.19M | $18.00K |
| 2023-12-31 | Reported | -$98.64M | (m) | (m) | $73.48M | -134.24% | $10.91M | -$56.26M | (m) | $64.78M | $49.73M | $83.00K |
| 2022-12-31 | Reported | -$107.1M | (m) | (m) | $65.05M | -164.65% | $49.90M | -$70.23M | (m) | $64.91M | $63.97M | $40.00K |
| 2021-12-31 | Reported | -$59.34M | (m) | (m) | $85.49M | -69.41% | $11.08M | -$70.83M | (m) | $49.31M | $47.70M | $14.00K |
| 2020-12-31 | Reported | -$36.39M | (m) | (m) | $78.65M | -46.27% | $3.25M | -$42.65M | (m) | $28.57M | $33.69M | $57.00K |
| 2019-12-31 | Reported | -$17.67M | (m) | (m) | $65.21M | -27.10% | $8.38M | -$18.07M | (m) | $22.42M | $22.08M | $9.00K |
| 2018-12-31 | Reported | -$10.7M | (m) | (m) | $37.77M | -28.34% | $7.85M | $5.57M | (m) | $14.30M | $11.27M | $7.00K |
| 2017-12-31 | Reported | -$20.95M | (m) | (m) | $9.39M | -223.01% | $5.16M | $290.00K | (m) | $9.92M | $9.90M | $5.00K |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Fortrea Holdings Inc. (FTRE) | United States | $1.903B | -19.43 |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| CareDx, Inc. (CDNA) | United States | $3.174B | 13.21 |
| BIODESIX INC (BDSX) | United States | $0.312B | |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |